Department of Justice January 2014 – Federal Register Recent Federal Regulation Documents

Agency Information Collection Activities: Proposed Collection; Comments Requested: Federal Firearms License (FFL) RENEWAL Application
Document Number: 2014-01844
Type: Notice
Date: 2014-01-30
Agency: Department of Justice, Bureau of Alcohol, Tobacco, Firearms and Explosives
Ralph J. Chambers, M.D.; Decision and Order
Document Number: 2014-01797
Type: Notice
Date: 2014-01-30
Agency: Drug Enforcement Administration, Department of Justice
House of Medicine; Decision and Order
Document Number: 2014-01794
Type: Notice
Date: 2014-01-30
Agency: Drug Enforcement Administration, Department of Justice
Importer of Controlled Substances; Notice of Registration; Clinical Supplies Management, Inc.
Document Number: 2014-01788
Type: Notice
Date: 2014-01-30
Agency: Drug Enforcement Administration, Department of Justice
Manufacturer of Controlled Substances; Notice of Registration; Halo Pharmaceutical, Inc.
Document Number: 2014-01785
Type: Notice
Date: 2014-01-30
Agency: Drug Enforcement Administration, Department of Justice
Importer of Controlled Substances; Notice of Registration; United States Pharmacopeial Convention
Document Number: 2014-01784
Type: Notice
Date: 2014-01-30
Agency: Drug Enforcement Administration, Department of Justice
Drug Enforcement Administration
Document Number: 2014-01782
Type: Notice
Date: 2014-01-30
Agency: Department of Justice
Controlled Substances: 2014 Proposed Aggregate Production Quota for Three Temporarily Controlled Synthetic Phenethylamines
Document Number: 2014-01778
Type: Notice
Date: 2014-01-30
Agency: Drug Enforcement Administration, Department of Justice
Three synthetic phenethylamines 2-(4-iodo-2,5- dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5), 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2- methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82), and 2- (4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36) were temporarily placed in schedule I of the Controlled Substances Act (CSA) by a final order published by the Drug Enforcement Administration (DEA) on November 15, 2013 (78 FR 68716). This means that any manufacturer that wishes to manufacture 25I-NBOMe, 25C-NBOMe, or 25B-NBOMe after November 15, 2013, must be registered with the DEA and have obtained a manufacturing quota for 25I-NBOMe, 25C-NBOMe, or 25B-NBOMe pursuant to 21 CFR part 1303. The DEA cannot issue individual manufacturing quotas for 25I-NBOMe, 25C-NBOMe, or 25B- NBOMe unless and until it establishes an aggregate production quota. Therefore, this notice proposes a 2014 aggregate production quota for 25I-NBOMe, 25C-NBOMe, and 25B-NBOMe.
Importer of Controlled Substances; Notice of Registration; Cambrex Charles City, Inc.
Document Number: 2014-01707
Type: Notice
Date: 2014-01-30
Agency: Drug Enforcement Administration, Department of Justice
Office of the Attorney General; Amendment of Americans with Disabilities Act Title II and Title III Regulations to Implement ADA Amendments Act of 2008
Document Number: 2014-01668
Type: Proposed Rule
Date: 2014-01-30
Agency: Department of Justice
The Department of Justice (Department) is issuing this Notice of Proposed Rulemaking (NPRM) to amend its Americans with Disabilities Act (ADA) regulations in order to incorporate the statutory changes to the ADA set forth in the ADA Amendments Act of 2008 (ADA Amendments Act or the Act), which took effect on January 1, 2009. Congress enacted the ADA Amendments Act in order to revise the ADA definition of ``disability'' and to ensure that the definition is broadly construed and applied without extensive analysis. In this NPRM, the Department is proposing to add new sections to its title II and title III ADA regulations at 28 CFR parts 35 and 36, respectively, to provide detailed definitions of ``disability'' and to make consistent changes in other sections of the regulations. The ADA Amendments Act authorizes the Attorney General to issue regulations consistent with the Act that implement the definitions of ``disability'' in sections 3 and 4 of the Act, including the rules of construction set forth in section 3. The Department invites written comments from members of the public on this proposed rule.
Manufacturer of Controlled Substances; Notice of Registration; Irix Manufacturing, Inc.
Document Number: 2014-01781
Type: Notice
Date: 2014-01-29
Agency: Drug Enforcement Administration, Department of Justice
Sunshine Act Meeting
Document Number: 2014-01616
Type: Notice
Date: 2014-01-28
Agency: Department of Justice, Parole Commission
Schedules of Controlled Substances: Temporary Placement of 10 Synthetic Cathinones into Schedule I
Document Number: 2014-01172
Type: Proposed Rule
Date: 2014-01-28
Agency: Drug Enforcement Administration, Department of Justice
The Deputy Administrator of the Drug Enforcement Administration (DEA) is issuing this notice of intent to temporarily schedule 10 synthetic cathinones into schedule I pursuant to the temporary scheduling provisions of the Controlled Substances Act (CSA). The 10 substances are: (1) 4-methyl-N-ethylcathinone (``4-MEC''); (2) 4-methyl-alpha-pyrrolidinopropiophenone (``4-MePPP''); (3) alpha- pyrrolidinopentiophenone (``[alpha]-PVP''); (4) 1-(1,3-benzodioxol-5- yl)-2-(methylamino)butan-1-one (``butylone''); (5) 2-(methylamino)-1- phenylpentan-1-one (``pentedrone''); (6) 1-(1,3-benzodioxol-5-yl)-2- (methylamino)pentan-1-one (``pentylone''); (7) 4-fluoro-N- methylcathinone (``4-FMC''); (8) 3-fluoro-N-methylcathinone (``3- FMC''); (9) 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one (``naphyrone''); and (10) alpha-pyrrolidinobutiophenone (``[alpha]- PBP''). This action is based on a finding by the Deputy Administrator that the placement of these synthetic cathinones into schedule I of the CSA is necessary to avoid an imminent hazard to the public safety. Any final order will be published in the Federal Register and may not be effective prior to February 27, 2014. Any final order will impose the administrative, civil, and criminal sanctions and regulatory controls applicable to schedule I substances under the CSA on the manufacture, distribution, possession, importation, exportation, research, and conduct of instructional activities of these synthetic cathinones.
Sunshine Act Meeting
Document Number: 2014-01614
Type: Notice
Date: 2014-01-27
Agency: Department of Justice, Parole Commission
Roderick Lee Mitchell, M.D.; Decision and Order
Document Number: 2014-01159
Type: Notice
Date: 2014-01-22
Agency: Drug Enforcement Administration, Department of Justice
Manufacturer of Controlled Substances, Notice of Application: Noramco, Inc.
Document Number: 2014-01158
Type: Notice
Date: 2014-01-22
Agency: Drug Enforcement Administration, Department of Justice
Importer of Controlled Substances; Notice of Application; Noramco, Inc.
Document Number: 2014-01157
Type: Notice
Date: 2014-01-22
Agency: Drug Enforcement Administration, Department of Justice
Importer of Controlled Substances; Notice of Registration; Noramco, Inc.
Document Number: 2014-01156
Type: Notice
Date: 2014-01-22
Agency: Drug Enforcement Administration, Department of Justice
Hearing of the Advisory Committee of the Attorney General's Task Force on American Indian/Alaska Native Children Exposed to Violence
Document Number: 2014-01139
Type: Notice
Date: 2014-01-22
Agency: Department of Justice, Office of Justice Programs
This is an announcement of the second hearing of the Advisory Committee of the Attorney General's Task Force on American Indian/ Alaska Native Children Exposed to Violence (hereafter referred to as the AIAN Advisory Committee). The AIAN Advisory Committee is chartered to provide the Attorney General with valuable advice in the areas of American Indian/Alaska Native children's exposure to violence for the purpose of addressing the epidemic levels of exposure to violence faced by tribal youth. Based on the testimony at four public hearings, on comprehensive research, and on extensive input from experts, advocates, and impacted families and tribal communities nationwide, the AIAN Advisory Committee will issue a final report to the Attorney General presenting its findings and comprehensive policy recommendations in the fall of 2014.
Meeting of the Federal Advisory Committee on Juvenile Justice
Document Number: 2014-01136
Type: Notice
Date: 2014-01-22
Agency: Department of Justice, Office of Justice Programs
The Office of Juvenile Justice and Delinquency Prevention (OJJDP) announces a webinar meeting of the Federal Advisory Committee on Juvenile Justice (FACJJ). This meeting is a continuation of the meeting that began on Monday, December 9, 2013. Due to inclement weather, the second day of the FACJJ meeting scheduled on Tuesday, December 10, 2013, had to be cancelled. Dates and Location: The meeting will take place online, as a webinar, on Friday, February 7, 2014, from 2 to 5 p.m. ET.
Notice of Federal Advisory Committee Meeting
Document Number: 2014-00943
Type: Notice
Date: 2014-01-21
Agency: Department of Justice
This notice announces a forthcoming public meeting of the National Commission on Forensic Science.
James Clopton, M.D.; Decision and Order
Document Number: 2014-00524
Type: Notice
Date: 2014-01-14
Agency: Drug Enforcement Administration, Department of Justice